Renal Replacement Therapy And Urologic Complications - USMLE Step 2

SECTION 1

Historical Context & Motivation

Before the advent of renal replacement therapy (RRT), end-stage renal disease (ESRD) was uniformly fatal. Patients with irreversible kidney failure had no viable treatment options, and uremia—the toxic accumulation of metabolic waste products—led to encephalopathy, pericarditis, and death within weeks. The development of dialysis and, later, renal transplantation transformed nephrology from a largely observational specialty into one with life-sustaining interventions. Understanding these therapies, their indications, their complications, and their intersection with urologic pathology is essential for any clinician managing patients with acute or chronic kidney disease.

1943 • First Practical Hemodialysis

Willem Kolff constructed the first rotating drum dialyzer in Nazi-occupied Netherlands, using cellophane tubing and a washing machine drum to successfully treat acute kidney injury, proving that extracorporeal blood purification was feasible.

1960 • Scribner Shunt for Chronic Access

Belding Scribner developed the external arteriovenous shunt, enabling repeated vascular access and making chronic maintenance hemodialysis a reality for patients with ESRD.

1966 • Brescia-Cimino AV Fistula

The native arteriovenous fistula was introduced as a superior, longer-lasting form of vascular access, dramatically reducing infection and thrombosis rates compared with external shunts.

1976 • Continuous Ambulatory Peritoneal Dialysis

Robert Popovich and Jack Moncrief introduced CAPD, allowing patients to perform dialysis at home via a permanent peritoneal catheter, broadening access and improving quality of life.

1990s • Modern Immunosuppression & Transplant Expansion

Introduction of tacrolimus and mycophenolate mofetil improved graft survival rates significantly, making renal transplantation the preferred long-term RRT for eligible patients.

Today, approximately 800,000 patients in the United States live with ESRD, with the majority relying on hemodialysis. Despite remarkable advances, the clinician must navigate a complex landscape of modality selection, vascular and peritoneal access complications, transplant immunology, and urologic emergencies such as obstructive uropathy and nephrolithiasis. The central question this lesson addresses is: how does a clinician choose and manage the appropriate renal replacement modality while recognizing and treating urologic complications that may precipitate or complicate kidney failure?

SECTION 2

Core Principles & Definitions

Renal replacement therapy encompasses any treatment that replaces the filtering function of the kidneys, and its three principal modalities—hemodialysis, peritoneal dialysis, and renal transplantation—differ fundamentally in mechanism, timing, and complication profile. Urologic complications, particularly obstructive uropathy and nephrolithiasis, represent both causes of renal failure requiring RRT and complications arising in the post-transplant or dialysis setting. A solid grasp of the foundational principles below enables rational clinical decision-making.

Diffusion & Ultrafiltration

Hemodialysis relies on diffusion of solutes across a semipermeable membrane along concentration gradients, while ultrafiltration uses hydrostatic pressure to remove excess fluid.

Peritoneal Membrane as Dialyzer

In peritoneal dialysis, the peritoneum serves as the semipermeable membrane. Osmotic agents (typically dextrose) in the dialysate create an osmotic gradient that drives fluid removal.

Transplant Immunology

Renal transplantation requires HLA matching and lifelong immunosuppression. Rejection is classified as hyperacute (minutes), acute (days–months), or chronic (years), each with distinct pathophysiology.

Obstructive Uropathy

Obstruction at any level of the urinary tract—from renal pelvis to urethra—raises intraluminal pressure, impairs glomerular filtration, and can produce post-renal AKI. Timely decompression is essential.

Indications for Emergent RRT

Remember the mnemonic AEIOU: Acidosis (refractory), Electrolyte abnormalities (hyperkalemia), Ingestions (toxic alcohols, lithium), Overload (volume), and Uremic symptoms.

✦

KEY TAKEAWAY

Think of the kidney as a sophisticated water treatment plant that filters waste, balances electrolytes, and regulates fluid volume. Hemodialysis is an external filtration plant connected via plumbing (vascular access); peritoneal dialysis is a portable unit that uses your body's own lining as the filter membrane; and transplantation is installing a brand-new treatment plant. Urologic complications—stones, strictures, masses—are blockages in the piping downstream of the plant, which can cause backup pressure that damages the plant itself.

SECTION 3

Visual Explanation — RRT Modalities Overview

The three pillars of renal replacement therapy are shown side by side. Hemodialysis (left) uses an external dialyzer with vascular access. Peritoneal dialysis (center) uses the peritoneal membrane with an indwelling catheter. Transplantation (right) provides the most physiologic replacement but requires lifelong immunosuppression.

As illustrated above, each RRT modality occupies a distinct niche. Hemodialysis remains the most commonly used modality in the United States, typically delivered in-center three times per week for approximately 3–4 hours per session. The dialyzer contains thousands of hollow fibers through which blood flows countercurrent to dialysate, maximizing concentration-gradient–driven solute removal. Peritoneal dialysis, by contrast, grants patients autonomy—continuous ambulatory peritoneal dialysis (CAPD) involves 4–5 manual exchanges per day, while automated peritoneal dialysis (APD) uses a cycler machine overnight. Transplantation offers the best long-term survival and quality of life but demands careful immunologic matching and carries unique surgical and immunosuppressive risks, including urologic complications at the ureteroneocystostomy site.

SECTION 4

Mechanisms of Solute Clearance & Fluid Removal

Although renal replacement therapy is a clinical rather than purely mathematical discipline, understanding the quantitative principles underlying dialysis adequacy is essential for USMLE Step 2 and for clinical practice. The primary measures of dialysis efficacy are Kt/V for hemodialysis and weekly Kt/V or creatinine clearance for peritoneal dialysis. These parameters guide clinicians in prescribing adequate treatment doses.

HEMODIALYSIS ADEQUACY

Kt/V ≥ 1.2 (single-pool, per session)

K = dialyzer clearance (mL/min); t = time on dialysis (min); V = volume of distribution of urea (mL). A Kt/V ≥ 1.2 per session (or URR ≥ 65%) is the minimum target recommended by KDOQI guidelines.

UREA REDUCTION RATIO

URR = (BUN₍pre₎ − BUN₍post₎) / BUN₍pre₎ × 100%

URR is a simpler, widely used surrogate for Kt/V. A URR ≥ 65% corresponds approximately to a single-pool Kt/V of 1.2. Values consistently below target prompt evaluation for access recirculation, reduced blood flow, or shortened treatment time.

PERITONEAL DIALYSIS ADEQUACY

Weekly Kt/V ≥ 1.7 (urea)

Peritoneal dialysis adequacy is assessed weekly. A weekly Kt/V ≥ 1.7 for urea is the minimum KDOQI target. Peritoneal equilibration testing (PET) classifies patients as high, high-average, low-average, or low transporters, which determines optimal dwell times and fluid management strategies.

Beyond urea kinetics, fluid removal deserves special emphasis. In hemodialysis, ultrafiltration is driven by transmembrane pressure—the hydrostatic pressure gradient across the dialyzer membrane. Excessive ultrafiltration rates (>13 mL/kg/hr) are associated with intradialytic hypotension, myocardial stunning, and increased mortality. In peritoneal dialysis, fluid removal depends on the osmotic gradient generated by dextrose or icodextrin in the dialysate. Over time, with recurrent peritonitis or prolonged exposure to hypertonic glucose solutions, the peritoneal membrane may undergo fibrosis and neoangiogenesis, leading to ultrafiltration failure—a common cause of technique failure in long-term peritoneal dialysis patients.

SECTION 5

Complications of Dialysis & Urologic Emergencies

Hemodialysis Complications

The most common acute complication of hemodialysis is intradialytic hypotension, occurring in 20–30% of sessions. It results from rapid fluid removal exceeding the plasma refill rate. Management includes reducing the ultrafiltration rate, administering isotonic saline boluses, and placing the patient in Trendelenburg position. Dialysis disequilibrium syndrome is a neurologic complication seen primarily in patients initiating dialysis with very high BUN levels; rapid urea clearance creates an osmotic gradient favoring cerebral edema. Prevention involves slow, shorter initial sessions. Vascular access complications—thrombosis, stenosis, and infection—are the leading cause of hospitalization in hemodialysis patients. AV fistulae have the lowest complication rate, followed by AV grafts and tunneled catheters, which carry the highest infection risk.

This flowchart illustrates the diagnostic and management approach to urinary obstruction. Renal ultrasound is the first-line imaging study. The presence of hydronephrosis prompts non-contrast CT to identify the etiology (stone, mass, or stricture). Management differs by stone size and the presence of infection. Infected hydronephrosis (pyonephrosis) is a urologic emergency requiring immediate decompression.

Peritoneal Dialysis Complications

The hallmark complication of peritoneal dialysis is peritonitis, diagnosed by cloudy effluent with a white cell count >100/μL (>50% neutrophils). The most common organisms are coagulase-negative staphylococci (touch contamination) and Staphylococcus aureus (exit-site infection ascending). Gram-negative peritonitis suggests a bowel source and warrants surgical evaluation. Treatment is empirical intraperitoneal antibiotics—typically vancomycin plus a third-generation cephalosporin or aminoglycoside—adjusted by culture. Failure to improve within 5 days mandates catheter removal. Other notable complications include protein malnutrition (peritoneal albumin losses of 5–15 g/day), encapsulating peritoneal sclerosis (rare but devastating), and metabolic derangements including hyperglycemia and hypertriglyceridemia from dextrose absorption.

Urologic Complications in Transplantation

Renal transplant recipients face unique urologic risks. Ureteral stenosis at the ureteroneocystostomy occurs in 2–10% of transplants, typically presenting with rising creatinine and graft hydronephrosis in the first 3 months. Ischemia of the distal ureter is the most common cause. Urinary leak presents earlier (first 1–2 weeks) with pain, declining urine output, and perinephric fluid on imaging; nuclear renography with Tc-99m MAG3 can confirm extravasation. Lymphocele is a collection of lymphatic fluid around the graft that can compress the ureter or iliac vein, presenting weeks to months post-transplant. Percutaneous drainage followed by marsupialization is the definitive treatment. Additionally, the immunosuppressed state predisposes transplant patients to BK virus nephropathy, which mimics rejection on biopsy and requires immunosuppression reduction rather than intensification.

SECTION 6

Worked Clinical Example

Clinical Vignette: Managing a Dialysis Patient with Acute Complications

1
Step 1 — Identify the Clinical Scenario

A 58-year-old woman on hemodialysis via a right internal jugular tunneled catheter presents with fever (38.9°C), chills, and hypotension (BP 85/55 mmHg). Blood cultures are drawn from the catheter and a peripheral site. She was dialyzed yesterday with a pre-dialysis BUN of 80 mg/dL and post-dialysis BUN of 32 mg/dL.

Suspected catheter-related bloodstream infection (CRBSI) with hemodynamic instability.
2
Step 2 — Calculate URR to Assess Adequacy

URR = (BUN_pre − BUN_post) / BUN_pre × 100% = (80 − 32) / 80 × 100% = 48 / 80 × 100% = 60%. This is below the target of ≥ 65%, suggesting inadequate dialysis—possibly due to catheter dysfunction or recirculation.

URR = 60% (subtherapeutic; target ≥ 65%)
3
Step 3 — Initiate Empiric Treatment for CRBSI

For suspected CRBSI with hemodynamic instability, empiric therapy must cover both gram-positive organisms (especially MRSA, common in catheter infections) and gram-negative bacilli. Start vancomycin plus an anti-pseudomonal agent (e.g., cefepime or gentamicin, renally dosed). Obtain differential time to positivity (DTP) from catheter and peripheral cultures—a DTP ≥ 2 hours suggests the catheter is the source.

Vancomycin + cefepime started; fluid resuscitation with isotonic saline.
4
Step 4 — Decide on Catheter Management

Given hemodynamic instability and high suspicion for CRBSI, IDSA guidelines recommend immediate catheter removal and placement of a temporary catheter at a different site for ongoing dialysis. If the patient were hemodynamically stable with an uncomplicated infection, antibiotic lock therapy with catheter salvage could be attempted, but S. aureus bacteremia, fungemia, or septic shock mandates catheter removal.

Tunneled catheter removed; temporary femoral catheter placed for dialysis access.
5
Step 5 — Long-Term Access Planning

This patient has been relying on a tunneled catheter, which carries the highest infection risk among HD access types. Once the bacteremia clears (negative blood cultures for 48–72 hours), the patient should be referred for creation of an arteriovenous fistula (AVF), the preferred permanent access with the lowest rates of infection and thrombosis. Fistula maturation typically takes 6–8 weeks; in the interim, a new tunneled catheter may be placed.

Refer to vascular surgery for AVF creation; goal to transition from catheter-dependent dialysis.

SECTION 7

Comparing RRT Modalities — Strengths & Limitations

Feature	Hemodialysis	Peritoneal Dialysis	Transplantation
Survival	5-year ~35–40%	5-year ~35–40% (comparable)	5-year ~85–95% (living donor); best long-term
Setting	In-center or home	Home-based	Surgical placement; outpatient follow-up
Major Complications	Hypotension, access thrombosis/infection, amyloidosis	Peritonitis, protein loss, ultrafiltration failure	Rejection, infection, PTLD, urologic complications
Hemodynamic Stability	Intermittent; risk of intradialytic hypotension	Continuous; better hemodynamic profile	Physiologic; no dialysis-related hemodynamic stress
Contraindications	Severe vascular disease, hemodynamic instability (use CRRT)	Prior abdominal surgery/adhesions, active abdominal infection, ileostomy	Active malignancy, active infection, non-adherence, severe cardiovascular disease
Quality of Life	Lower (dietary restrictions, time commitment)	Moderate (independence, but body image issues)	Highest (near-normal lifestyle)

Comparison of the three RRT modalities across clinical features

✦

KEY TAKEAWAY

Transplantation is analogous to replacing a failed engine with a new one—it restores the most physiologic function but requires ongoing maintenance (immunosuppression) and carries surgical risk. Hemodialysis is like hooking up to an external filtration machine at a service center—effective but intermittent and tethered. Peritoneal dialysis is a portable, always-on filter built into your chassis—convenient but with unique wear-and-tear issues. The best modality depends on patient anatomy, comorbidities, social support, and personal preference.

SECTION 8

Connection to Advanced Concepts — CRRT, Rejection, & Transplant Immunology

In the intensive care setting, hemodynamically unstable patients with AKI cannot tolerate conventional intermittent hemodialysis. Continuous renal replacement therapy (CRRT) provides slow, continuous solute and fluid removal over 24 hours, minimizing the hemodynamic swings that characterize intermittent HD. The most common CRRT modality is continuous venovenous hemodiafiltration (CVVHDF), which combines diffusion and convection. CRRT is particularly important in patients with cerebral edema, septic shock, or multiorgan failure where intravascular volume shifts must be minimized.

Feature	Intermittent HD	CRRT
Duration	3–4 hours, 3× weekly	24 hours/day, continuous
Hemodynamic effect	Rapid fluid shifts; hypotension common	Gradual fluid removal; well-tolerated in shock
Setting	Outpatient or inpatient	ICU only
Drug clearance	Significant; dose adjustments needed post-HD	Continuous; dosing adjustments for antibiotics, anticoagulants
Anticoagulation	Heparin or none	Citrate (regional) preferred; lower bleeding risk

Intermittent HD vs. CRRT

Transplant immunology represents a rich frontier beyond the scope of basic RRT. The types of allograft rejection—hyperacute (preformed antibodies, minutes to hours, graft must be removed), acute cellular (T-cell mediated, weeks to months, treated with pulse steroids or antithymocyte globulin), acute antibody-mediated (donor-specific antibodies, treated with plasmapheresis and IVIG), and chronic (months to years, interstitial fibrosis and tubular atrophy, irreversible)—are high-yield USMLE topics. Understanding these categories and their histologic patterns (tubulitis for cellular, C4d deposition for antibody-mediated) is essential for differentiating rejection from other causes of allograft dysfunction such as calcineurin inhibitor toxicity, BK nephropathy, or recurrent disease.

💡

USMLE Pearl

A transplant patient with rising creatinine and a biopsy showing tubulitis with lymphocytic infiltration has acute cellular rejection → treat with pulse methylprednisolone. If the biopsy shows C4d staining in peritubular capillaries, suspect antibody-mediated rejection → plasmapheresis + IVIG. If viral cytopathic changes with "decoy cells" in urine and SV40 staining on biopsy → BK nephropathy → reduce immunosuppression.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 62-year-old man with ESRD on hemodialysis via a tunneled catheter develops recurrent Staphylococcus aureus bacteremia despite appropriate antibiotics. What is the most important next step in management, and why does catheter-dependent hemodialysis carry a higher infection risk than an arteriovenous fistula?

Show answer

The most important next step is removal of the tunneled catheter and placement of temporary access at a different site, followed by referral for AV fistula creation. Tunneled catheters carry the highest infection risk among hemodialysis access types because they provide a direct conduit between the skin surface and the central venous system. Biofilm formation on the catheter surface harbors bacteria and protects them from antibiotics, making eradication without catheter removal extremely difficult, particularly with S. aureus. AV fistulae, by contrast, are entirely subcutaneous with no external hardware, have high blood flow rates that resist stasis and thrombosis, and are associated with the lowest rates of infection and hospitalization.

Question 2: BASIC CALCULATION

A patient on hemodialysis has a pre-dialysis BUN of 90 mg/dL and a post-dialysis BUN of 27 mg/dL. Calculate the urea reduction ratio (URR) and determine whether this session achieved adequate dialysis per KDOQI guidelines.

Show answer

URR = (BUN_pre − BUN_post) / BUN_pre × 100% = (90 − 27) / 90 × 100% = 63 / 90 × 100% = 70%. The KDOQI guideline recommends a URR ≥ 65% (corresponding to a single-pool Kt/V ≥ 1.2). At 70%, this session meets the adequacy target. If this patient's URR were consistently below 65%, the clinician should investigate catheter malfunction, access recirculation, shortened dialysis time, or inadequate blood flow rates.

Question 3: INTERMEDIATE

A 45-year-old woman on CAPD presents with abdominal pain, fever, and cloudy dialysate. Her peritoneal fluid shows 450 WBC/μL with 80% neutrophils. Gram stain reveals gram-positive cocci in clusters. Outline the initial management and describe the criteria that would prompt catheter removal.

Show answer

This presentation is consistent with PD-associated peritonitis, most likely due to Staphylococcus species given the gram-positive cocci in clusters. Initial management includes: (1) Send peritoneal fluid for cell count, differential, culture, and sensitivity; (2) Initiate empiric intraperitoneal antibiotics—typically vancomycin (for gram-positive coverage) combined with a third-generation cephalosporin or aminoglycoside (for gram-negative coverage), administered intraperitoneally with each exchange; (3) Ensure adequate pain management. Indications for catheter removal include: failure to improve after 5 days of appropriate antibiotic therapy (refractory peritonitis), relapsing peritonitis (same organism within 4 weeks of completing treatment), fungal peritonitis (which mandates immediate catheter removal), or evidence of a surgical abdomen suggesting a bowel source. In this case, if cultures confirm coagulase-negative Staphylococcus and the patient responds to vancomycin, the catheter may be salvaged.

Question 4: APPLIED

A 50-year-old man who received a deceased-donor kidney transplant 3 months ago presents with a rising creatinine (from 1.2 to 2.8 mg/dL over 2 weeks) and ultrasound shows moderate hydronephrosis of the allograft with no perinephric fluid collection. What is the most likely diagnosis, what is the underlying mechanism, and how should this be managed?

Show answer

The most likely diagnosis is ureteral stenosis at the ureteroneocystostomy, which occurs in 2–10% of renal transplants and typically manifests within the first 3–6 months. The underlying mechanism is ischemia of the distal donor ureter—the transplanted ureter receives its blood supply from the renal artery via small ureteral branches, and the distal segment is vulnerable to ischemic injury, fibrosis, and subsequent stricture formation. Technical factors during anastomosis (tension, kinking) may also contribute. Management begins with percutaneous nephrostomy for decompression and antegrade nephrostogram to define the anatomy of the stricture. Definitive treatment options include endoscopic balloon dilation with ureteral stent placement, or surgical revision (reimplantation of the ureter) if endoscopic approaches fail. It is essential to rule out other causes of graft dysfunction (acute rejection, calcineurin inhibitor toxicity, BK nephropathy) with biopsy if the clinical picture is ambiguous.

Question 5: CRITICAL THINKING

A 35-year-old renal transplant recipient on tacrolimus, mycophenolate, and prednisone presents 8 months post-transplant with rising creatinine, decoy cells in urine, and a positive serum BK viral PCR (>10,000 copies/mL). Renal biopsy shows interstitial inflammation with viral cytopathic changes and positive SV40 immunostaining. However, the Banff classification also identifies borderline changes suggestive of acute cellular rejection. How would you reconcile these findings and what is the appropriate management strategy?

Show answer

This clinical scenario illustrates one of the most challenging diagnostic dilemmas in transplant nephrology: the coexistence or mimicry of BK virus nephropathy and acute cellular rejection. BK nephropathy and acute rejection can present with identical clinical features (rising creatinine, interstitial inflammation on biopsy), and the inflammatory response to BK virus can produce borderline rejection-like changes. The SV40 immunostaining and high serum BK viral load (>10,000 copies/mL) strongly support BK nephropathy as the dominant pathology. The presence of viral cytopathic changes (ground-glass nuclear inclusions) further confirms active viral replication within tubular epithelial cells. Management requires immunosuppression reduction—the opposite of what one would do for pure rejection. Standard approach includes reducing mycophenolate dose by 50% or discontinuing it, and targeting lower tacrolimus trough levels (4–6 ng/mL). If serum BK viral load does not decrease over 4–6 weeks, additional interventions such as switching from tacrolimus to a lower-potency calcineurin inhibitor or adding leflunomide or cidofovir (off-label) may be considered. Treating for rejection (pulse steroids, antithymocyte globulin) in this context would worsen BK nephropathy by further suppressing the immune system's ability to control viral replication. Serial BK PCR monitoring and repeat biopsy guide further management. This scenario underscores the critical importance of tissue diagnosis, as empiric treatment for presumed rejection without biopsy could lead to graft loss.

SUMMARY

Summary — Renal Replacement Therapy & Urologic Complications

Summary

Renal replacement therapy encompasses three modalities: hemodialysis (external dialyzer using diffusion and ultrafiltration; target URR ≥ 65% / Kt/V ≥ 1.2; complications include intradialytic hypotension, access thrombosis, and catheter-related bloodstream infections), peritoneal dialysis (peritoneal membrane as dialyzer; osmotic dextrose gradient; major risk is peritonitis diagnosed by >100 WBC/μL with >50% neutrophils in effluent), and renal transplantation (best long-term survival; requires lifelong immunosuppression and HLA matching). Emergent dialysis indications follow the AEIOU mnemonic: Acidosis, Electrolytes (hyperkalemia), Ingestions, Overload, Uremia.

Urologic complications span the spectrum from obstructive uropathy and nephrolithiasis (causing post-renal AKI; diagnosed by ultrasound then CT; infected hydronephrosis is a urologic emergency) to transplant-specific issues: ureteral stenosis (ischemic, 2–10% of transplants), urinary leak (early post-op), lymphocele, and BK virus nephropathy (mimics rejection; requires immunosuppression reduction, not intensification). Rejection subtypes—hyperacute, acute cellular, acute antibody-mediated, and chronic—each have distinctive timelines, histology, and treatments. CRRT provides continuous, hemodynamically gentle solute and fluid removal for critically ill ICU patients who cannot tolerate intermittent HD.